Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods by unknown
RESEARCH ARTICLE Open Access
Detection of HPV DNA in paraffin-
embedded cervical samples: a comparison
of four genotyping methods
Felipe A. Castro1, Jill Koshiol1, Wim Quint2, Cosette M. Wheeler4, Maura L. Gillison3, Laurence M. Vaughan5,
Bernhard Kleter2, Leen-Jan van Doorn2, Anil K. Chaturvedi1, Allan Hildesheim1, Mark Schiffman1, Sophia S. Wang6,
Rosemary E. Zuna7, Joan L. Walker7, S. Terence Dunn7 and Nicolas Wentzensen1,8*
Abstract
Background: Identification of human papillomavirus (HPV) DNA in cervical tissue is important for understanding
cervical carcinogenesis and for evaluating cervical cancer prevention approaches. However, HPV genotyping using
formalin-fixed, paraffin-embedded (FFPE) tissues is technically challenging. We evaluated the performance of four
commonly used genotyping methods on FFPE cervical specimens conducted in different laboratories and
compared to genotyping results from cytological samples.
Methods: We included 60 pairs of exfoliated-cell and FFPE specimens from women with histologically confirmed
cervical intraepithelial lesions grade 2 or 3. Cytology specimens were genotyped using the Linear Array assay. Four
expert laboratories processed tissue specimens using different preparation methods and then genotyped the
resultant sample preparations using four different HPV genotyping methods: SPF10-PCR DEIA LiPA25 (version 1),
Inno-LiPA, Linear Array and the Onclarity assay. Percentage agreement, kappa statistics and McNemar’s chi-square
were calculated for each comparison of different methods and specimen types.
Results: Overall agreement with respect to carcinogenic HPV status for FFPE samples between different methods
was: 81.7, 86.7 and 91.7 % for Onclarity versus Inno-LiPA, Linear Array and SPF-LiPA25, respectively; 81.7 and 85.0 %
for Linear Array versus Inno-LiPA and SPF-LiPA25, respectively; and 86.7 % for SPF-LiPA25 versus Inno-LiPA.
Type-specific agreement was >88.3 % for all pair-wise comparisons. Comparisons with cytology specimens resulted
in overall agreements from 80 to 95 % depending on the method and type-specific agreement was >90 % for
most comparisons.
Conclusions: Our data demonstrate that the four genotyping methods run by expert laboratories reliably detect
HPV DNA in FFPE specimens with some variation in genotype-specific detection.
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Background
The causal role of HPV in cervical carcinoma has been
well established. Persistent infection with one of 13–15
oncogenic types of human papillomavirus (HPV) is a ne-
cessary cause of cervical cancer [1, 2]. Diagnosis of HPV
infection is usually performed from cervical cytology
specimens and used in natural history studies, imple-
mentation of screening programs, and follow-up of vac-
cination studies [3, 4]. However, cytology specimens often
contain larger numbers of HPV infections [5], most of
which are thought to be transient infections, whereas it is
assumed that a lesion is caused by one genotype [6, 7].
Thus, identification of HPV in tissue specimens is import-
ant to ascertain the causal type involved in HPV-related
carcinogenesis.
Detection and classification of HPV infection through
polymerase chain reaction (PCR)-based methods has
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been successfully implemented in cervical cytology spec-
imens [8]. Genotyping methods for HPV vary by target
sequence and amplicon size. Most assays target the L1
gene and some the viral oncogenes E6/E7. Amplicon sizes
range from 65 base pairs (SPF10 primers) to 450 base pairs
(PGMY09/11 primers). Standard genotyping methods for
cytology specimens often cannot be easily applied to tissue
specimens. Particularly, formalin fixation may cause exten-
sive DNA damage, including cross-linking and fragmenta-
tion [9, 10]. Consequently, it has been reported that
successful amplification of HPV sequences from archival
FFPE specimens is inversely correlated to the length of the
amplicon of the PCR method and that specimen age
may contribute to degradation [11, 12]. Furthermore,
differences in sample processing and DNA extraction
of FFPE materials may explain discrepancies observed
in the performance of specific genotyping methods for
FFPE specimens [13–15]. Several recent reports suggest
that the use of robust extraction methods can improve
the performance of nucleic acid tests when applied to
fixed specimen types [16–18].
Given the importance of accurately identifying HPV
present in FFPE materials and the lack of studies compar-
ing HPV assays in tissue specimens, we evaluated HPV
genotyping methods in FFPE specimens using four HPV
genotyping methods, representing frequently-used assays
with well-documented performance in cervical specimens.
The laboratories participating in this comparison have
long-standing experience in HPV genotyping and they
have participated in many inter-laboratory comparisons,
including WHO HPV LabNet proficiency testing.
Methods
Study population
The materials for this study were obtained from the
Study to Understand Cervical Cancer Early Endpoints
and Determinants (SUCCEED), a cross-sectional study
including women referred to the University of Oklahoma
from November 2003 to September 2009 for abnormal
cervical screening results. SUCCEED design and method-
ology, including the details on enrollment, questionnaire
data, HPV DNA genotyping, histology, and cytology pro-
cedures, have been described in depth elsewhere [19, 20].
Participants (median age 30.0 years) signed informed con-
sent, completed interviewer-administered, standardized
questionnaires and provided liquid-based cytology speci-
mens for ThinPrep Pap and HPV genotyping. According
to management guidelines, most histologically confirmed
high-grade lesions diagnosed as cervical intraepithelial
neoplasia grade 2 (CIN2) and all CIN3 were treated by
loop electrosurgical excision procedure (LEEP) of the
transformation zone.
For the present study, we selected 60 women diag-
nosed with CIN2+ (29 CIN2 and 31 CIN3) for whom
tissue blocks were available and who had cytology-based
HPV DNA genotyping results. The median duration be-
tween cytology sampling and LEEP was 27.5 days. In 26
women, cytology and LEEP were done on the same day.
Institutional Review Board approval for this study was
provided by University of Oklahoma and the U.S. Na-
tional Cancer Institute.
HPV genotyping of cytology specimens
HPV detection and genotyping in cytology specimens
was done using the Linear Array HPV Genotyping Test
(Roche Molecular Diagnostics), as previously described
[19, 20]. Briefly, the Linear Array assay is a type-specific,
PGMY09/11 L1 primer PCR-based assay for 37 HPV
types, 13 high- and 24 low-risk HPV types (6, 11, 16, 18,
26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58,
59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83,
84, and 89). HPV 52 is not determined directly by a
type-specific probe but rather by a probe that cross hy-
bridizes with HPV 33, 35, 52, and 58. The presence of
HPV 52 was inferred only if the cross-reactive probe
was hybridized but there was no hybridization detected
for the HPV 33, 35 and 58 type-specific probes. Notably,
concurrent infections of type 52 with the three other
types cannot be detected. The procedure followed rec-
ommendations of the manufacturer with the variations
that DNA was isolated from 1 mL of exfoliated cells in
PreservCyt using Qiagen DNeasy Blood and Tissue Kit,
10 μL of template DNA was amplified, and the amplified
products were hybridized and detected using an auto-
mated Auto-line probe assay (LiPA) staining system using
2.5 mL of each reagent per strip. The Linear Array results
on the strips were evaluated by two independent ob-
servers. An unambiguous, continuous band was judged to
indicate a positive result.
Tissue sectioning
A series of 4-μm-thick tissue sections was cut from each
paraffin block. The first and last sections were stained
with hematoxylin and eosin (H&E) to confirm the diag-
nosis of CIN2+. Each participating laboratory received
two unstained 4um sections for HPV genotyping. Stand-
ard measures to avoid cross-contamination were taken
during tissue sectioning and processing.
HPV genotyping of tissue specimens
One of four HPV genotyping methods was used to geno-
type tissue specimens in each specific laboratory: 1) the
The BD Onclarity™ HPVAssay (denoted as “Onclarity”); 2)
the Inno-LiPA system (denoted as “Inno-LiPA”); 3) the
PGMY09/11 Linear Array (denoted as “Linear Array”);
and 4) SPF10-DEIA and LiPA25 (denoted as “SPF-
LiPA25”). The main features of each HPV method are
listed in Table 1 and described below. All FFPE sections,
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including those that tested HPV-negative, were positive
for human DNA controls
Onclarity assay
The BD Onclarity™ HPV Assay (BD Diagnostics, Sparks,
USA) is a real-time PCR assay that detects type-specific
E6 and E7 genomic DNA. It simultaneously detects all
14 high-risk HPV types, and can provide genotyping
information on six individual genotypes (HPV 16, 18, 31,
45, 51 and 52), reporting the remaining HPV types in
three distinct groups (33 and 58; 56, 59 and 66; and 35,
39 and 68). Each FFPE patient sample was extracted
using the automated workflow on the Viper™ LT system.
The section was combined with 0.5 mL of distilled water
and added directly to a tube with pierceable cap contain-
ing a proprietary diluent. The sample was then lysed dir-
ectly using the Viper™ LT Pre-warm station before being
transferred onto the deck of the instrument where it
underwent automated sample processing and PCR de-
tection. Briefly, the DNA was extracted using BD FOX™
magnetic particles and the eluate-containing DNA was
used to set up three PCR genotyping reactions: G1 de-
tects HPV 16, HPV 18 and HPV 45 plus the internal
beta globin control; G2 detects HPV 31, HPV 33_58 and
HPV 56_59_66 plus the internal beta globin control; G3
detects HPV 51, HPV 52 and HPV 35_39_68 plus the
internal beta globin control. After 40 PCR cycles, any Ct
score for a specific genotype and/or the internal beta
globin control was considered positive for that channel.
Inno-LiPA assay
DNA was purified from paraffin-embedded material as
previously described [21]. Purified DNA was evaluated
for the presence of HPV DNA by use of the Inno-LiPA
assay (Innogenetics, Gent, Belgium), an assay that uti-
lizes the SPF10 consensus primer system to amplify a
65 bp fragment of the L1 region of HPV, followed by
reverse line blot hybridization to HPV type-specific
immobilized probes for 18 high-risk/ possibly high-risk
(16, 18, 25, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66,
68, 73, 82) and 7 low-risk (6, 11, 40, 43, 44, 54, 70) HPV
types. In addition to the internal assay control, testing
for human DNA was conducted from all specimens
(ERV3). The line probe assays are evaluated by two inde-
pendent observers and were adjudicated by a third ob-
server when different results are reported, which did not
occur in this study.
Linear array assay
Without removal of paraffin wax, the tissue sections ob-
tained for HPV genotyping were resuspended (50–125 μl)
in 10 mM Tris pH 8.0 containing 1 mm EDTA, 0.1 %
Laureth-12 and 1 mg/ml proteinase K (PK) and digested
with shaking at 65 °C for 4 h followed by overnight at 37 °
C. Prior to polymerase chain reaction (PCR)-based HPV
genotyping, PK was inactivated at 95 °C for 15 min.
Microfuge tubes were immediately centrifuged briefly at
13,000 X g while the paraffin-wax was liquefied and an
aqueous-wax interface formed upon cooling. Two and five
microliters of the aqueous digest from each tissue speci-
men were used for genotyping with the LINEAR ARRAY
HPV Genotyping Test (HPV LA; Roche Diagnostics,
Indianapolis, Indiana USA). The LA HPV Genotyping
Test is a qualitative test for 37 HPV genotypes incorporat-
ing selective PCR amplification with biotinylated PGMY
09/11 L1 region consensus primers and colorimetric de-
tection of amplified products bound to immobilized HPV
genotype –related oligonucleotide probes on a LINEAR
ARRAY HPV genotyping strip. PGMY-based HPV geno-
typing with the HPV LA have been previously reported in
detail [22, 23]. Using the Roche HPV LA detection kit,
hybridizations were automated using Tecan ProfiBlot-48
robots (Tecan, Austria) as previously described [24]. Two
independent readers interpreted the presence of HPV
Table 1 Formalin-fixed and paraffin embedded (FFPE) specimen processing, cytology specimens and human papillomavirus (HPV)
testing methods
Cytology specimens HPV genotyping methods/protocol for FFPE specimens
Characteristics Linear array Onclarity Inno-LiPA Linear array SPF-LiPA25
Deparaffinization NA No Yes No No
DNA extraction Crude extraction One-step heat / chemical





Crude extraction Crude extraction









16, 18, 31, 33, 35, 39, 45, 51,
56, 58, 59, 66, 68 and 52/
33/35/58
16, 18, 31, 45, 51, 52, 33/
58, 39/68/35, and 59/
56/66
16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66,
and 68
16, 18, 31, 33, 35, 39,
45, 51, 56, 58, 59, 66,
68, and 52/33/35/58
16, 18, 31, 33, 35, 39,




450 79-137 65 450 65
Onclarity, The BD Onclarity™ HPV Assay; Inno-LiPA, The Inno-LiPA system; Linear Array, The PGMY09/11 Linear Array, and SPF-LiPA25, The SPF10-DEIA, LiPA25
(version 1) NA, not applicable; HPV 52 is positively identified in the linear Array when the presence of HPV 33, 35, and 58 is excluded
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genotypes using a reference template provided by the
manufacturer. Any discrepancies identified between the
two readers were adjudicated by a third review.
SPF-LiPA25 assay
Total DNA was isolated from FFPE tissue material by
proteinase K treatment, 250 μl proteinase K lysis buffer
was added and incubated at 56 °C for 16–24 h. Protein-
ase K was heat-inactivated by incubation at 96 °C for
10 min. Each DNA isolation run and PCR run contained
HPV positive and negative controls.
Specimens were tested for HPV DNA by PCR amplifi-
cation/typing using the HPV SPF10 PCR DEIA and
LiPA25 version 1 assay (Labo Biomedical Products, Rijs-
wijk, The Netherlands) based on licensed Innogenetics
technology [25, 26]. The SPF10 PCR primer set detects a
broad spectrum of HPV genotypes by amplification of a
small fragment of 65 bp from the L1 region of HPV.
Reverse primers contain a biotin label at the 5’ end,
enabling capture of the reverse strand onto streptavidin-
coated microtiter plates. Captured amplimers are then
denatured by alkaline treatment, and detected by a de-
fined cocktail of digoxigenin-labeled probes, allowing de-
tection of a broad spectrum of HPV genotypes. This
method is designated an HPV DNA enzyme immuno-
assay (DEIA), and the results are an optical density
value. When a sample is HPV positive by DEIA, the
same SPF10 amplimer is also used to identify the HPV
genotype by reverse hybridization to the LiPA25 genotyp-
ing strip (version 1). This line probe assay contains
probes for 25 different HPV genotypes (i.e., HPV types
6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52,
53, 54, 56, 58, 59, 66, 68/73, 70, and 74). The test results,
purple lines on a LiPA strip are visually scored by two
independent readers. In case of a discrepant line score a
third reader determines the final outcome. In this study
there were no different scores.
In SPF10 DEIA positive samples the presence of HPV
16 and 18 was also tested by type-specific (TS) PCR pri-
mer sets. TS16 and TS18 amplimers were detected by
DEIA, similar to the method for SPF10 amplimer detec-
tion. The final genotyping result is the outcome of the
testing algorithm [27]. As a result of this algorithm
HPV16 and HPV 18 were only detected by type specific
PCR three times and one time, respectively. These types
were found in the presence of another HPV type. The
SPF10 LiPA assay does not use an internal human DNA
control. Two specimens were negative for all HPV types
and 10fold dilution with and without spiking using
HPV16 as a target did not indicate PCR inhibition.
Statistical analyses
Analyses were limited to 14 HPV types classified as car-
cinogenic (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, 68) [2] and samples positive for other HPV types
were considered as negative for HPV. We calculated
overall and type-specific prevalence for high-risk HPV
types detected in exfoliated cells by Linear Array and in
FFPE specimens across all different methods.
To evaluate the performance of each method in FFPE
tissue samples, we compared FFPE HPV genotyping re-
sults between different HPV methods. However, pair-
wise comparisons were restricted to those carcinogenic
types for which a specific probe was available across all
of the different methods. Thus, comparison across all
four assays was possible for types 16, 18, 31, 45, 51 and
52, and across 3 assays (Inno-LiPA, Linear Array and
SPF-LiPA25) for types 33, 35, 39, 56 and 58, and 66.
HPV type 68 genotyping was only compared between
Linear Array and Inno-LiPA. HPV genotyping concord-
ance was tested by calculating overall and type-specific
percentages of agreement and kappa values. McNemar’s
chi-square was calculated to test for significance (p < 0.05)
in the pattern of disagreement.
An indirect analysis that may allow a further evalu-
ation of the performance of these four genotyping
methods in FFPE samples is compare FFPE genotyping
results with those of their paired cytological sample.
HPV genotyping results from FFPE specimens for each
of the four assays was compared to results from cytology
specimens as described above, and by creating three cat-
egories of agreement: (i) Identical: when the same num-
ber and type of HPV was identified in both specimens;
(ii) Compatible: when at least one HPV type was found
in common; and (iii) Discrepant: when no type was iden-
tified in common or the FFPE sample was HPV negative.
This classification was performed, first by including all
single and combined HPV type probes available in each
of the assays and second, by including only single
probes.
Results
Overall and type-specific HPV prevalence
All 60 exfoliated cell specimens were positive for at least
one of the 14 carcinogenic HPV genotypes tested by
Linear Array (Table 2). The most prevalent types were
HPV16 (53.3 %), 18 (15.0 %), 31 and 45 (both 13.3 %).
Multiple HPV types were found in 35 % of the exfoliated
cell specimens.
Eighty percent or more of the FFPE specimens were
positive for at least one HPV type in each of the four
methods (Table 2). Type-specific positivity ranged across
different HPV methods from 0 % (for HPV 35, 59, 66,
and 68 in some of the tested methods) to 48.3 % (for
HPV 16 using the SPF-LiPA25 method). The SPF-LiPA25
assay identified more types at both the overall and the
type-specific level. Detection of multiple types was rare
among FFPE specimens by all methods (from 5.0 % in
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the Inno-LiPA to 18.3 % in the SPF-LiPA25). There was a
notable difference in the detection rate of multiple types
between tests with the Onclarity and SPF-LiPA25 method
detecting 2–3 times more multiple types than those de-
tected by the Inno-LiPA and Linear Array methods
(Table 2). Genotyping results for each of the participants
are provided in Additional file 1: Table S1. Only one speci-
men was negative across all methods. In three cases,
Onclarity detected types that were not found with any of
the other assays. Six specimens were repeated in three
labs; only one repeat results showed a partial discrepancy
(Additional file 2: Table S2).
Multiple HPV genotypes were detected in 21 of the 60
exfoliated cell specimens. In the corresponding FFPE
specimen multiple genotypes were only detected in eight
specimens by at least one of the four different genotyp-
ing assays. This observation can be explained by the fact
that exfoliated cell specimens cover the complete cervix
area, whereas FFPE specimens are taken at a specific site
of the cervix epithelium.
Agreement between tissue-based HPV testing across
HPV methods
Overall concordance between tissue-based HPV results
across laboratory methods was good (Table 3); the over-
all percent agreement ranged from 81.7 for Inno-LiPA
compared with Linear Array and with Onclarity to 91.7 %
for SPF-LiPA25 compared with Onclarity. The number of
samples with HPV types detected was lower when samples
were genotyped by Linear Array compared with the num-
ber of positive samples obtained by SPF-LiPA25 (McNe-
mar’s p-value =0.004). Percentage of agreement for the
two most common HPV types, 16 and 18, ranged from
88.3 % (SPF-LiPA25 vs. Onclarity) to 95 % (Onclarity vs.
Linear Array) for HPV 16 and from 95 % (SPF-LiPA25 vs.
Linear Array and Onclarity vs. Linear Array) to 98.3 %
(Onclarity vs. Inno-LiPA and SPF-LiPA25 vs. Inno-LiPA)
for HPV 18, but none of the differences were statistically
significant. Summarized across all types, the percent iden-
tical, compatible and discrepant results for each assay
combination is shown in Additional file 3: Table S3.
Table 2 Human papillomavirus (HPV) genotyping results for paired cytology and tissue specimensa by genotyping method (%)
Cytology FFPE samples
HPV, type Linear Array Onclarity Inno-LiPA Linear Array SPF-LiPA25
Any oncogenicb 60 (100.0) 54 (90.0) 51 (85.0) 48 (80.0) 57 (95.0)
Single probes
HPV 16 32 (53.3) 26 (43.3) 25 (41.7) 24 (40.0) 29 (48.3)
HPV 18 9 (15.0) 8 (13.3) 7 (11.7) 5 (8.3) 8 (13.3)
HPV 31 8 (13.3) 7 (11.7) 7 (11.7) 6 (10.0) 7 (11.7)
HPV 33 2 (3.3) NA 2 (3.3) 2 (3.3) 2 (3.3)
HPV 35 1 (1.7) NA 0 0 0
HPV 39 4 (6.7) NA 2 (3.3) 2 (3.3) 2 (3.3)
HPV 45 8 (13.3) 5 (8.3) 2 (3.3) 3 (5.0) 5 (8.3)
HPV 51 6 (10.0) 1 (1.7) 2 (3.3) 1 (1.7) 2 (3.3)
HPV 52 NA 5 (8.3) 3 (5.0) NA 6 (10.0)
HPV 56 4 (6.7) NA 1 (1.7) 1 (1.7) 1 (1.7)
HPV 58 5 (8.3) NA 3 (5.0) 3 (5.0) 3 (5.0)
HPV 59 2 (3.3) NA 0 2 (3.3) 1 (1.7)
HPV 66 4 (6.7) NA 0 0 1 (1.7)
HPV 68 2 (3.3) NA 0 1 (1.7) NA
Combined probes
52/33/35/58c 6 (10.0) NA NA 2 (3.3) NA
33/58 NA 5 (8.3) NA NA NA
35/39/68 NA 3 (5.0) NA NA NA
56/59/66 NA 4 (6.7) NA NA NA
68/73 NA NA NA NA 2 (3.3)
Multiple infectionsd 21(35.0) 10 (16.6) 3 (5.0) 4 (6.7) 11 (18.3)
a Genotyping results for 60 paired cytology- and formalin-fixed and paraffin embedded (FFPE) specimens in the SUCCEED study; Onclarity, The BD Onclarity ™ HPV
Assay; Inno-LiPA, The Inno-LiPA system; Linear Array, The PGMY09/11 Linear Array, and SPF-LiPA25, The SPF10-DEIA, LiPA25 (version 1);
b includes a specimen
positive for any of the 14 HPV types; c HPV 52 was positively identified by the Linear array test when the presence of HPV 33, 35, and 58 was excluded; d Multiple
infections included individual HPV types or combined types; NA, not applicable
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Table 3 Human papillomavirus (HPV) genotyping agreement for tissue specimens* tested with four different genotyping methods
HPV Method 1 Method 2 Percenta Kappa
Type Name Positive Name Positive agreement Value 95 % CI P
Oncogenicb
Any Onclarity 54 Inno-LiPA 51 81.7 0.2 −0.15 0.48 0.5
Any Onclarity 54 Linear Array 48 86.7 0.5 0.19 0.78 0.07
Any Onclarity 54 SPF-LiPA25 57 91.7 0.4 −0.01 0.82 0.4
Any Linear Array 48 Inno-LiPA 51 81.7 0.4 0.07 0.67 0.5
Any Linear Array 48 SPF-LiPA25 57 85.0 0.3 0.05 0.65 0.004
Any SPF-LiPA25 57 Inno-LiPA 51 86.7 0.3 −0.06 0.62 0.07
By single probe
16 Onclarity 26 Linear Array 24 90.0 0.79 0.64 0.95 0.7
16 Onclarity 26 Inno-LiPA 25 91.7 0.83 0.69 0.97 1.0
16 Linear Array 24 Inno-LiPA 25 95.0 0.9 0.78 1.0 1.0
16 SPF-LiPA25 29 Onclarity 26 88.3 0.77 0.6 0.93 0.5
16 SPF-LiPA25 29 Inno-LiPA 25 90.0 0.8 0.65 0.95 0.2
16 SPF-LiPA25 29 Linear Array 24 91.7 0.83 0.69 0.97 0.1
18 Onclarity 8 Inno-LiPA 7 98.3 0.92 0.78 1.0 1.0
18 Onclarity 8 Linear Array 5 95.0 0.74 0.47 1.0 0.3
18 Linear Array 5 Inno-LiPA 7 96.7 0.82 0.57 1.0 0.5
18 SPF-LiPA25 8 Linear Array 5 95.0 0.74 0.47 1.0 0.3
18 SPF-LiPA25 8 Inno-LiPA 7 98.3 0.92 0.78 1.0 1.0
18 SPF-LiPA25 8 Onclarity 8 96.7 0.86 0.66 1.0 1.0
31 Onclarity 7 Inno-LiPA 7 96.7 0.84 0.62 1.0 1.0
31 Onclarity 7 Linear Array 6 98.3 0.91 0.75 1.0 1.0
31 Linear Array 6 Inno-LiPA 7 98.3 0.91 0.75 1.0 1.0
31 SPF-LiPA25 7 Linear Array 6 98.3 0.91 0.75 1.0 1.0
31 SPF-LiPA25 7 Onclarity 7 96.7 0.84 0.62 1.0 1.0
31 SPF-LiPA25 7 Inno-LiPA 7 100 NA NA NA NA
33 Linear Array 2 Inno-LiPA 2 100 NA NA NA NA
33 SPF-LiPA25 2 Linear Array 2 100 NA NA NA NA
33 SPF-LiPA25 2 Inno-LiPA 2 100 NA NA NA NA
35 Linear Array 0 Inno-LiPA 0 NA NA NA NA NA
35 SPF-LiPA25 0 Inno-LiPA 0 NA NA NA NA NA
35 SPF-LiPA25 0 Linear Array 0 NA NA NA NA NA
39 Linear Array 2 Inno-LiPA 2 100 NA NA NA NA
39 SPF-LiPA25 2 Inno-LiPA 2 100 NA NA NA NA
39 SPF-LiPA25 2 Linear Array 2 100 NA NA NA NA
45 Onclarity 5 Inno-LiPA 2 91.7 0.25 −0.19 0.69 0.4
45 Onclarity 5 Linear Array 3 93.3 0.47 0.03 0.91 0.6
45 Linear Array 3 Inno-LiPA 2 95.0 0.38 −0.18 0.93 1.0
45 SPF-LiPA25 5 Linear Array 3 96.7 0.73 0.38 1.0 0.5
45 SPF-LiPA25 5 Inno-LiPA 2 95.0 0.55 0.11 0.99 0.3
45 SPF-LiPA25 5 Onclarity 5 96.7 0.78 0.49 1.0 1.0
51 Onclarity 1 Inno-LiPA 2 98.3 0.66 0.04 1.0 1.0
51 Onclarity 1 Linear Array 1 100 NA NA NA NA
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Agreement between exfoliated-cell- and tissue-based
HPV testing
Identical HPV results between cytology and FFPE were
found in 53.3 % (Onclarity), 56.7 % (Inno-LiPA), 53.3 %
(Linear Array), and 61.7 % (SPF-LiPA25) of the cases
(Table 4); an additional 25.0 to 33.3 % were categorized
as compatible HPV results and 5.0 to 21.7 % as discrep-
ant results, meaning no type agreement or sample is
HPV negative. Almost all discrepant results were related
to a negative test result.
The overall agreement of HPV status between exfoliated-
cell and FFPE specimens across the four tested methods
was 90 % for Onclarity, 85.0 % for Inno-LiPA, 80 % for
Linear Array, and 95 % for SPF-LiPA25 (Table 4). When
considering individual types, the percentage agreement
ranged from 83.3 % (HPV16) to 98.3 (HPV52) for the
Onclarity method, 88.3 % (HPV16) to 100 % (HPV33) for
the SPF-LiPA25 and the Inno-LiPA methods, and from
86.7 % (HPV 16) to 100 % (HPV33 and 59) for the Linear
Array method. Detection for HPV16 and 45 tested for the
Inno-LiPA method and for HPV16 for the Linear Array
were significantly lower in FFPE samples compared to de-
tection in exfoliated specimens (McNemar’s p-value of
0.02 and 0.03, and 0.01, respectively).
Discussion
Very few studies have evaluated the performance of two
or more methods in parallel in FFPE specimens [28–30].
In the present study, we evaluated simultaneously four
different methods that not only varied in the set of
primers used, but also in the sample processing and
DNA extraction protocols of the independent laborator-
ies. Even with such marked differences in the protocols,
we observed good overall performance for all methods
in the detection of HPV in FFPE specimens.
With the exception of the Onclarity assay, the geno-
typing performance of these HPV methods has been
previously evaluated in FFPE specimens. Our findings
are very much in agreement with other reports indicat-
ing a good to excellent performance of SPF-LiPA25,
Inno-LiPA and the Linear Array method. Previous stud-
ies evaluating the SPF-LiPA25 assay in FFPE and cytology
Table 3 Human papillomavirus (HPV) genotyping agreement for tissue specimens* tested with four different genotyping methods
(Continued)
51 Linear Array 1 Inno-LiPA 2 98.3 0.66 0.04 1.0 1.0
51 SPF-LiPA25 2 Linear Array 1 98.3 0.66 0.04 1.0 1.0
51 SPF-LiPA25 2 Onclarity 1 98.3 0.66 0.04 1.0 1.0
51 SPF-LiPA25 2 Inno-LiPA 2 100 NA NA NA NA
52 Onclarity 5 Inno-LiPA 3 93.3 0.47 0.03 0.91 0.6
52 Onclarity 5 Linear Array 2 95.0 0.55 0.11 0.99 0.3
52 Linear Array 2 Inno-LiPA 3 98.3 0.79 0.4 1.0 1.0
52 SPF-LiPA25 6 Linear Array 2 93.3 0.47 0.05 0.9 0.1
52 SPF-LiPA25 6 Inno-LiPA 3 95.0 0.64 0.27 1.0 0.3
52 SPF-LiPA25 6 Onclarity 5 95.0 0.7 0.38 1.0 1.0
56 Linear Array 1 Inno-LiPA 1 100 NA NA NA NA
56 SPF-LiPA25 1 Linear Array 1 100 NA NA NA NA
56 SPF-LiPA25 1 Inno-LiPA 1 100 NA NA NA NA
58 Linear Array 3 Inno-LiPA 3 100 NA NA NA NA
58 SPF-LiPA25 3 Linear Array 3 100 NA NA NA NA
58 SPF-LiPA25 3 Inno-LiPA 3 100 NA NA NA NA
59 Linear Array 2 Inno-LiPA 0 NA NA NA NA NA
59 SPF-LiPA25 1 Linear Array 2 98.3 0.66 0.04 1.0 1.0
59 SPF-LiPA25 1 Inno-LiPA 0 NA NA NA NA NA
66 Linear Array 0 Inno-LiPA 0 NA NA NA NA NA
66 SPF-LiPA25 1 Inno-LiPA 0 NA NA NA NA NA
66 SPF-LiPA25 1 Linear Array 0 NA NA NA NA NA
68 Linear Array 1 Inno-LiPA 0 NA NA NA NA NA
* Genotyping agreement for 60 formalin-fixed and paraffin embedded (FFPE) specimens in the SUCCEED study; Onclarity, The BD Onclarity™ HPV Assay; Inno-LiPA,
The Inno-LiPA system; Linear Array, The PGMY09/11 Linear Array, and SPF-LiPA25, The SPF10-DEIA, LiPA25 (version 1); p, p-value of the McNerman test;
b Any,
includes a specimen positive for any of the 14 HPV types; NA, not apply or cannot be calculated; HPV 52 was positive when there was a test negative for HPV 33,
35, and 58 individually but positive for the combined probe 52/33/35/58 (for Linear Array)
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specimens found an overall percentage agreements
greater than 90 %[13, 15, 31]. The SPF-LiPA25 has been
also compared with other methods, such as the Geno-
mica assay (primers MY09/1) [29] and the Linear Array
assay [28], with similar results. Although there were
methodological differences in those studies (genotyping
method used for cytology specimens, grade of cervical
lesion and time window between the testing of the cyto-
logical and tissue specimens), they all reported good
agreement between SPF10-LiPA25 and the other tests.
The SPF-LiPA25 method uses the general primer set, de-
signed as SPF10, which amplifies a fragment of only
65 bp of L1 region of the HPV genome [26]. This primer
set has a high sensitivity for HPV detection, which
makes it particularly suitable for assessing HPV in FFPE
specimens.
Good performance for the Inno-LiPA method in FFPE
versus cytology specimens has been also reported in pre-
vious studies. One Italian study compared the Inno-LiPA
genotyping results from FFPE samples with the Linear
Array results from the paired cytology specimens and
reported an overall kappa value of 0.85 [14]. Similarly, a
Slovenian study compared the performance of a real
time PCR assay versus the Inno-LiPA method in 31
FFPE cervical cancer specimens, reporting 100 % geno-
type agreement [32]. The Inno-LiPA method also per-
formed well in FFPE specimens from other HPV-related
cancers, such as head and neck [33] and vulva [30, 34].
To our knowledge, no previous study has compared
FFPE samples tested by Linear Array with cytological re-
sults by Linear Array or any other method. We saw
similar HPV genotyping results for FFPE and cytology
specimens tested by Linear Array (agreement 80 %). As
mentioned above, Linear Array has been directly com-
pared with SPF-LiPA25 and with Inno-LiPA in FFPE cer-
vical [35] and vulvar specimens [30], respectively. Such
studies showed good concordance between the methods
for detecting any high-risk types. However, both previ-
ous studies [30, 35] and our study found that the sensi-
tivity of Linear Array was lower compared to other
methods. The lower sensitivity of Linear Array in FFPE
samples could be attributed to DNA fragmentation; the
Table 4 Human papillomavirus (HPV) genotyping agreement for paired cytology and tissue specimensa tested with different
genotyping methods
Overall agreement Onclarity Inno-LiPA Linear Array SPF-LiPA25
with cytology N (%) N (%) N (%) N (%)
Identical 32 (53.3) 34 (56.7) 32 (53.3) 37 (61.7)
Compatible 19 (31.7) 17 (28.3) 15 (25.0) 20 (33.3)
Discrepant 9 (15.0) 9 (15.0) 13 (21.7) 3 (5.0)
HPV type %a kappa p %b kappa p %a kappa p %a kappa p
Any oncogenic typec 90.0 NA 85.0 NA 80.0 NA 95.0 NA
Single probe
HPV 16 83.3 0.7 0.1 88.3 0.8 0.02 86.7 0.7 0.01 88.3 0.8 0.5
HPV 18 95 0.8 1.0 96.7 0.9 0.5 93.3 0.7 0.1 98.3 0.9 1.0
HPV 31 95 0.8 1.0 98.3 0.9 1.0 96.7 0.8 0.5 98.3 0.9 1.0
HPV 33 NA 100 1.0 NA 100 1.0 NA 100 1.0 NA
HPV 35 NA 98.3 NA 98.3 NA 98.3 NA
HPV 39 NA 96.7 0.7 0.5 96.7 0.7 0.5 96.7 0.7 0.5
HPV 45 91.7 0.6 0.1 90.0 0.4 0.03 91.7 0.5 0.1 95.0 0.7 0.3
HPV 51 91.7 0.3 0.1 93.3 0.5 0.1 91.7 0.3 0.1 93.3 0.5 0.1
HPV 52d 98.3 0.9 1.0 95.0 0.6 0.3 93.3 0.5 0.1 96.7 0.8 1.0
HPV 56 NA 95.0 0.4 0.3 95.0 0.4 0.3 95.0 0.4 0.3
HPV 58 NA 96.7 0.7 0.5 96.7 0.7 0.5 96.7 0.7 0.5
HPV 59 NA NA 100 1.0 NA 98.3 0.7 1.0
HPV 66 NA NA NA 95.0 0.4 0.3
HPV 68 NA NA 98.3 0.7 1.0 NA
a Genotyping agreement for 60 paired cytology- and formalin-fixed and paraffin embedded (FFPE) specimens in the SUCCEED study; Onclarity, The BD Onclarity™
HPV Assay; Inno-LiPA, The Inno-LiPA system; Linear Array, The PGMY09/11 Linear Array, and SPF-LiPA25, The SPF10-DEIA, LiPA25 (version 1); Identical, same number
and type identified; Compatible, at least one type in common identified; Discrepant, no type in common identified or FFPE sample HPV negative; a Only single
probes, but including probe combined probe 52/33/35/58 for Linear Array;b Percentage of overall agreement; c Includes a specimen positive for any of the 14 HPV
types; d HPV 52 was positively identified in the linear Array test when the presence of HPV 33, 35, and 58 was excluded; p, p-value of the McNemar test; NA, not
apply or cannot be calculated
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Linear Array method targets an amplicon region much
larger than other methods (450 bp), which can result in
reduced amplification efficiency [36]. A limitation of
Linear Array is the lack of an individual probe for HPV
52. Since HPV52 is detected in a mixed probe together
with HPV-33, −35, or −58, multiple infections between
HPV52 and one of these types cannot be detected.
Our study is the first one to test the Onclarity geno-
typing method using FFPE specimens. Previous studies
have found that this method performs well in cytology
specimens in comparison with other methods such as Hy-
brid Capture 2, Linear Array and Line Blot Assay [37].
Likewise a comprehensive study that compared seven
genotyping methods in cytology specimens showed that
Onclarity assay has a sensitivity of 95 % for detection of
CIN3+ [38]. Thus, the good performance of Onclarity in
FFPE specimens is consistent with previous studies using
cytology specimens. The BD Onclarity™ HPV Assay (BD
Diagnostics) uses real-time PCR to detect 14 HR HPV
types, six of which are tested individually while the
remaining HPV types are grouped (33_58), (56_59_66)
and (35_39_68). The HPV typing using multiple types in a
single channel prevented the evaluation of the type spe-
cific agreement for these combined types and may limit
the use of the assay when individual genotyping of these
combined types is required.
We observed that independent of the genotyping
method used, overall HPV prevalence (any type versus
none) in the FFPE specimens (between 80 to 95 % across
methods) was lower than in cytology specimens (100 %
with Linear Array), as has been found in some previous
studies [7, 15, 31], but not others [13]. Although the
sample size was too limited for a formal test, we did not
see evidence of type-specific failures for any of the evalu-
ated methods (Additional file 1: Table S1). We noted a
difference in the detection of multiple types, with the
Onclarity and SPF-LiPA25 tests detecting more multiple
types than either the Inno-LiPA or Linear Array tests.
This may be related to smaller target sequences of these
two assays, or to the previously described reduced per-
formance of select L1 primer designs in detecting mul-
tiple infections [39]. While a smaller amplicon size
could potentially have a higher risk of cross-sample con-
tamination, we did not observe any sign of contamin-
ation in our study.
DNA fragmentation and DNA-protein cross-linking by
formaldehyde exposure, as well as the presence of paraf-
fin, can impact both DNA yield and PCR amplification
efficiency. Our study evaluated combinations of DNA
extraction methods and HPV genotyping assays per-
formed in different laboratories. Therefore, the differ-
ences observed in this study cannot be directly
attributed to assay performance versus the DNA extrac-
tion approach used. However, generally, the differences
between results from different laboratories were minor
and seemed to be related mostly to amplicon size.
Strengths of the current analysis are the complete
histological characterization of the selected specimens,
and the short interval between cytological and histological
specimen collection. A limitation of our study was the lack
of parallel genotyping data from cytology specimens for all
the tested genotyping methods.
Conclusions
HPV genotyping from FFPE tissues showed high intra-
and inter-laboratory reproducibility in our study; the use
of any of the tested HPV genotyping methods in expert
laboratories can provide reliable identification of the
most important high risk HPV types in FFPE specimens.
However, there remains concern that reliability of tissue-
based genotyping may be worse in less experienced and
less rigorous laboratories, as indicated by a WHO HPV
laboratory comparison study including 29 centers across
the world, which reported lower proficiency measures
for HPV detection despite the use of standardized DNA
samples [40], rather than whole tissue sections as in the
current study. Thus, it can be expected that there is higher
variation of proficiency for tissue-based genotyping in less
experienced and less rigorous laboratories.
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